Blood is a vital and limited resource in the brain. All aspects of neuronal and non-neuronal activity require a supply of oxygen and glucose -- a need that constantly evolves with changes in brain activity (Fox and Raichle, [@B25]; Leybaert, [@B43]). How is the distribution of blood controlled relative to these changing needs? More basically, what are the signals that different classes of cells use to communicate changes in their metabolic load? How are these signals integrated to change the flow in the blood vessels that intercalate cortical neurons and glia (Figure [1](#F1){ref-type="fig"})?

![**Three dimensional vectorized reconstruction of all of the cell soma and blood vessels in a slab of mouse cerebral cortex**. Features in the raw data are analyzed and transformed into a digital map that represents them as cylinders and spheres with vector coordinates and associated radii. The vascular network is in red, the neuronal nuclei are in green, and non-neuronal nuclei are in yellow. The total volume is a 600-μm × 900-μm × 250-μm. Derived from Tsai et al. ([@B68], [@B69]).](fnene-03-00001-g001){#F1}

An understanding of neurovascular signaling bears directly on the limit to cortical function and, more generally, on resource management by the central nervous system. From a clinical perspective, understanding the relation of neuronal activity to changes in blood oxygen and flow is an essential step toward addressing the role of vascular dysfunction and disease in dementia (Paulson et al., [@B58]; Kövari et al., [@B41]). From the perspective of cognitive science, a quantitative understanding of neurovascular signaling is crucial for the interpretation of functional brain images (LeDoux et al., [@B42]) -- especially those obtained with blood oxygenation level dependent functional magnetic resonance imaging (BOLD fMRI). Magnetic resonance imaging and other macroscopic diagnostic techniques have provided a "window" into the brain from which modulation of macroscopic blood by neuronal activity may be assessed (Belliveau et al., [@B6]; Ogawa et al., [@B56]). These techniques are likely to evolve into essential tools for judging cognitive capabilities in a clinical setting and may be critical for the early identification and hopefully containment of dementia.

We view neurovascular control in terms of the net action of a tractable number of signaling molecules that arrive via one global and two local pathways (Figure [2](#F2){ref-type="fig"}). All of these function in a push--pull manner, i.e., one set of signals induces vasodilation through relaxation of arteriole smooth muscle, while a second set induces vasoconstriction (Cauli et al., [@B12]). The first local pathway involves local inhibitory interneurons that act directly on smooth muscle. Different subclasses of interneurons co-release different transmitters that act to either dilate vessels, including nitric oxide (NO) and vasoactive intestinal peptide (VIP), or to constrict vessels, including the neuropeptides somatostatin (SOM) and neuropeptide Y (NPY). In some cases the same interneuron can cause both effects; e.g., some SOM-expressing cells further express nitric oxide synthetase (Kawaguchi, [@B39]). Additional evidence for a role of interneurons in the modulation of blood flow comes from an increase in flow concurrent with γ-band oscillations in inhibitory networks (Niessing et al., [@B54]). Increases in flow correlate with such global rhythms. It is thus natural to hypothesize that the competition between dilation and constriction depends on the relative activation of different inhibitory networks (Gibson et al., [@B27]); this hypothesis may be tested with cell-specific markers of neuronal activity.

![**Cartoon of three signaling pathways, two local and one global, that can both constrict and dilate the arteriole vasculature**. Inhibitory interneurons can drive dilation via nitric oxide (NO), catalyzed by nitric oxide synthetase (NOS), and vasoactive intestinal peptide (VIP), and drive constriction via somatostatin (SOM) and neuropeptide Y (NPY). Astrocytes can dilate via protoglandin E (PG~E~) and epoxyeicosatrienoic acid (EET) and constrict via 20-Hydroxyeicosatetraenoic acid (20-HETE). Lastly, extrinsic input of acetylcholine (ACh) will dilate while serotonin (5HT) will constrict. Derived from Cauli et al. ([@B12]).](fnene-03-00001-g002){#F2}

The second local pathway for the control of blood flow originates with excitatory neurons and acts via astrocytes (Filosa et al., [@B23]; Iadecola and Nedergaard, [@B36]). Volume conduction of the excitatory transmitter glutamate can cause an increase in intracellular Ca^2+^ in astrocytes, which in turn initiates the conversion of arachidonic acid to the dilators prostaglandin E (PG~E~) and epoxyeicosatrienoic acid (EET) or the constrictor 20-hydroxyeicosatetraenoic acid (20-HETE). Recent work shows that the competition between dilation and constriction depends on the partial pressure of oxygen (pO~2~) (Gordon et al., [@B30]); dilation dominates at low pO~2~.

Lastly, global pathways involve the vasodilator acetylcholine (ACh) and the constrictor serotonin (5HT), released from their respective subcortical nuclei, i.e., nucleus basalis magnocellularis and the dorsal raphe nucleus (Hamel, [@B32], [@B33]). An additional neural pathway for the modulation of cortical blood flow occurs via the rostral ventrolateral medulla (RVLM; Golanov and Reis, [@B29]), whose projections to cortex are relayed by the interlaminar thalamic nucleus. Neurons in the RVLM are sensitive to oxygen levels. Their activation causes bilateral increase in cortical blood flow via thalamic intermediates. This raises the possibility that changes in cortical blood flow and activity are slaved to fluctuations in breathing and blood oxygenation (Wise et al., [@B75]; Shmueli et al., [@B61]; Drew et al., [@B19]). Blood flow is further driven by cortical state (Jones et al., [@B38]); this mode of control may well lie in changes in the patterns of activation of excitatory cells and subpopulations of inhibitory cells (Figure [2](#F2){ref-type="fig"}) that may involve modulatory control via Ach and 5HT pathways, as well as noradrenergic inputs (NA) from locus coeruleus (Cohen et al., [@B15]).

Potential Focus of an Experimental Program
==========================================

We consider competition among vasoactive pathway that predominantly effect parenchymal microvessels. We hypothesize that microvascular tone may be defined as a function of the local concentration of specific signaling molecules, such as EET, 20-HETE, NO, NPY, PG~E~, SOM, and VIP. The driving term is neuronal activity, which may be a one-to-one function of the neuronal stimulus for primary sensory areas. Formally, we seek a relation of the form
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where the functionalities, denoted *f*, are yet to be determined. Nonetheless, this general formalism emphasizes the need to study muscle tension on a cell type-by-type or transmitter-by-transmitter basis. It further reinforces the need to map the geometry of the vasculature (Figure [1](#F1){ref-type="fig"}) and the location of neuronal control regions (Figure [2](#F2){ref-type="fig"}).

The greatest uncertainty in the hypothesis that the control of cortical blood flow depends on the balance of neurotransmitters that lead to vasoconstriction versus dilation is that much of our understanding of signaling comes from experiments with brain slice preparations. Not only is vascular pressurization absent, but responses take place on tens of seconds (Cauli et al., [@B12]; Gordon et al., [@B30]), while the vasculature responds to changes in neuronal activity on the 0.5-s time-scale *in vivo*. It remains an open issue if signaling is faster *in vivo*, although such long times are observed when astrocytic Ca^2+^ levels are directly excited *in vivo* (Wang et al., [@B73]; Figure [3](#F3){ref-type="fig"}).

![**Two-photon laser scanning microscopy with arbitrary scan pathways to record from functionally labeled cells and vessels**. **(A)** Neurons and glia are labeled with the Ca^2+^ reporter Oregon Green BAPTA-1 AM and glia have sulforhodamine 101 as an additional label. Blood plasma is stained with fluorescein so that blood cell motion is measured. **(B)** Intensity along the scan path records Ca^2+^ signals and blood cell movement. **(C)** Traces of functional changes in intracellular Ca^2+^ and flood flow; note flow changes concurrent with stimulation. Algorithms from Helmchen and Kleinfeld ([@B35]), Drew et al. ([@B18]), Driscoll et al. ([@B20]).](fnene-03-00001-g003){#F3}

A first approach to define the inputs and output to a model of neurovascular coupling is to measure the activity of identified cell types concurrent with blood flow in a neighboring microvessel. The activity of neurons and glia in cortex may be established by measuring their internal calcium levels with optical contrast agents (Garaschuk et al., [@B26]; Figure [3](#F3){ref-type="fig"}) and *in vivo* two-photon laser scanning microscopy (TPLSM; Svoboda et al., [@B64]; Figure [3](#F3){ref-type="fig"}). Similarly, both the speed of blood cells and vascular tone may be concurrently established with two-photon microscopy (Helmchen and Kleinfeld, [@B35]; Figure [3](#F3){ref-type="fig"}). The clarity of these measurements depends on the ability to record from specific cell types and the specificity of co-release of different neuropeptides by interneurons. This implies the need to use transgenic animals that either express a functional indicator in specific cell types or, as a more general approach, to use mice that express Cre recombinase in specific cell types (Luo et al., [@B46]; Bernard et al., [@B7]; Table [1](#T1){ref-type="table"}). Cre recombinase drives the labeling of these cells types by crossing these mouse lines with fluorescent reporter mice (Madisen et al., [@B48]), in which a member of the fluorescent protein (FP) family (Tsien, [@B71]; Shaner et al., [@B60]) and/or a genetically encoded functional indicator is coded between lox-sites (Wallace et al., [@B72]; Table [2](#T2){ref-type="table"}); Cre recombinase activates sequences between these sites (Mallo, [@B49]). A complementary and common method is to infect cells that express Cre recombinase with a virus whose genetic material is modified to code a fluorescent indicator between lox-sites (Table [2](#T2){ref-type="table"}). As a technical issue, a construct with double lox-sites improves specificity of Cre recombinase targeting strategies (Atasoy et al., [@B5]).

###### 

**Mice that express fluorescent proteins or Cre recombinase in cell-types relevant to neurovascular regulation**.

  Promotor                           Expression                Goal                                                                              Jax number               References
  ---------------------------------- ------------------------- --------------------------------------------------------------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------
  hGFAP                              eGFP                      Visualization of cortical astrocytes                                                                       Nolte et al. ([@B55])
  GAD67                              GFP                       Visualization of parvalbumin, calretinin, or somatostatin-positive interneurons   003718, 007677, 006334   Oliva Jr. et al. ([@B57]); Tamamaki et al. ([@B66]); Chattopadhyaya et al. ([@B13]); Ma et al. ([@B47])
  Camk2a                             tdTomato (a red FP)       Visualization of cortical excitatory neurons                                                               Madisen et al. ([@B48])
  Camk2a                             Cre recombinase           Gene targeting to cortical excitatory neurons                                     005359                   Tsien et al. ([@B70])
  hGFAP                              Cre recombinase           Gene targeting to cortical astrocytes                                             004600                   Brenner et al. ([@B9]); Zhuo et al. ([@B80])
  Parvalbumin                        Cre recombinase           Gene targeting of parvalbumin-positive cortical interneurons                      008069                   Wulff et al. ([@B76])
  Smooth muscle myosin heavy chain   Cre recombinase and GFP   Gene targeting and visualization of pial vascular smooth muscle                   007742                   Xin et al. ([@B77],[@B78])

###### 

**Viral expression cassettes for *in vivo* manipulation and detection of astrocyte and interneuronal signaling**.

  Protein expressed                                             Goal                                                         Targeting strategies                     References
  ------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------- ----------------------------------------------------
  Channelrhodopsin 2                                            Light-mediated cell depolarization                                                                    Arenkiel et al. ([@B4]); Gradinaru et al. ([@B31])
  Halorhodopsin                                                 Light-mediated cell hyperpolarization                        \(i\) Cre-lox                            Zhang et al. ([@B79]); Chow et al. ([@B14])
  Archaerhodopsin-3                                                                                                          \(ii\) Cell type -- specific promoters   
  hM3Dq (G-coupled protein receptor for cell activation)        Drug-based (clozapine-N-oxide) regulation of activity        \(iii\) Cell type -- trophic viruses     Alexander et al. ([@B2])
  TRPV1                                                         Ligand-based (capsaicin) regulation of activity                                                       Arenkiel et al. ([@B3])
  Tn-XXL or GCaMP3 (Fluorescent protein based Ca^2+^ sensors)   Cell-specific detection of intracellular calcium increases                                            Mank et al. ([@B50]); Tian et al. ([@B67])

A second, albeit related approach is to manipulate the output of the neurons and astrocytes that release signaling factors and measure the volume concentration of signaling molecules, particularly under conditions of changing vascular dilation versus constriction. The activity of neurons and glia may be manipulated with photoexcitation of caged molecules, with ectopic expression of chemical receptors modified to have unnatural affinities to a specific drug (Alexander et al., [@B2]), with ectopic expression of receptors with native binding sites (Arenkiel et al., [@B3]), and with optogenetic agents that are targeted to specific cell types (Cardin et al., [@B10], [@B11]; Sohal et al., [@B63]). The latter strategy includes the use of channelrhodopsin (ChR2) to depolarize cells (Boyden et al., [@B8]; Arenkiel et al., [@B4]; Gradinaru et al., [@B31]) and halorhodopsin (NpHR; Zhang et al., [@B79]) or archaerhodopsin-3 (Arch; Chow et al., [@B14]) to inactivate cells. Other agents act directly on specific G-protein coupled pathways (Airan et al., [@B1]). All of these agents are typically delivered by viral injection in combination with Cre recombinase labeled animals, as described above (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). A complementary strategy is the use of short hairpin RNA (shRNAs) to silence specific cell signaling pathways labeled animals, as described above (Table [3](#T3){ref-type="table"}).

###### 

**Viral expression cassettes for *in vivo* genetic manipulation of astrocyte and interneuronal signaling**.

  shRNA target                                                Pathway                                 Targeting strategies   References
  ----------------------------------------------------------- --------------------------------------- ---------------------- --------------------------------------------------------------------------
  mGluR                                                       Astrocyte glutamate signaling pathway                          Zonta et al. ([@B81])
  phospholipase A~2~, cyclo-oxygenase-1, or cytochrome p450   Astrocyte arachidonic acid metabolism                          Zonta et al. ([@B81]); Mulligan and MacVicar ([@B52])
  Ca^2+^ sensitive large conductance BK channels              Astrocytic potassium release                                   Filosa et al. ([@B24]); Weaver et al. ([@B74]); Girouard et al. ([@B28])
  VIP or vascular receptor VPAC1                              Interneuron VIP release                 Cre-lox                Fahrenkrug et al. ([@B22]); Cauli et al. ([@B12])
  NOS                                                         Interneuron NO release                                         Cauli et al. ([@B12]); Enager et al. ([@B21])
  SOM or vascular receptor SSTR                               Interneuron SOM release                                        Cauli et al. ([@B12]); Enager et al. ([@B21]); Kocharyan et al. ([@B40])
  NPY or vascular receptor NPY-Y1                             Interneuron NPY release                                        Cauli et al. ([@B12])

The presence of multiple sources for the different signaling molecules suggests the additional need to measure receptor activation by these molecules directly. Receptor activation via the volume conduction of vasoactive signaling molecules may be observed with new cell-based indicators, CNiFERs, that can be made sensitive to any molecule that has a G-coupled protein receptor (Figures [4](#F4){ref-type="fig"}A,B). In a first realization with ACh sensing as the task, HEK cells were transfected with the muscarinic (M1) G~q~-protein receptor along with the \[Ca^2+^\]~int~ reporter TN-XXL (Heim and Griesbeck, [@B34]). These show a strong response to the release of endogenous ACh (Figures [4](#F4){ref-type="fig"}C,D). CNiFER technology may be extended, by the use of G~i/o~- and G~s~-protein receptors and chimeric Gα-q proteins (Coward et al., [@B16]), to sense neuropeptides such as VIP and SOM.

![**Overview of CNiFER methodology**. **(A)** Schematic of the cell-based sensors with a Gq family, G-protein coupled receptor for acetylcholine and the TN-XXL genetically expressible calcium reporter. **(B)**. Cartoon of the injection of CNiFERs and the placement of microelectrodes in rat frontal cortex. **(C)** *In vivo* response of M1-CNiFERs to cholinergic input after electrical activation of nucleus basalis (NBM). The X--Z scan was obtained with TPLSM through the depth of cortex before and after activation of cholinergic neurons in NBM. **(D)** Time dependence of the M1-CNiFER response, together with control data from CNiFERs without the M1 receptor, and the electrocorticogram (ECoG). The decrease in amplitude of the ECoG after stimulation, as expected for cholinergic activation of cortex. Adapted from Nguyen et al. ([@B53]).](fnene-03-00001-g004){#F4}

*In toto*, the combination of many *in vivo* tools, including electrophysiology, *in vivo* two-photon imaging, intracellular ion measurements (Figure [3](#F3){ref-type="fig"}), neurotransmitter receptor activation measurements (Figure [4](#F4){ref-type="fig"}), microdialysis measurements, single vessel blood flow measurements (Figure [3](#F3){ref-type="fig"}) as well as direct measurement of the activation of smooth muscle (Figure [5](#F5){ref-type="fig"}), and measurement of tissue oxygen levels (Sakadzic′ et al., [@B59]), can allow one to assess the influence of single neurons and networks of neurons on vascular control. These can be further supported by optical and chemical activation of specific cell types, as illustrated by the optical activation of astrocytes to increase blood flow in neighboring capillaries (Figure [6](#F6){ref-type="fig"}) in a manner similar to that seen with caged compounds (Takano et al., [@B65]). Lastly, automated reconstruction techniques allow one to map local architectonics (Figure [1](#F1){ref-type="fig"}). In all such endeavors, it important to realize that one may conceive new tools as they are required. One anticipated need is a calcium-clamp to control smooth muscle tension, possibly realized with caged molecules and optical indicators, as a means to fix the flow in a region and observe changes in signaling molecule concentration.

![***In vivo* measurements of arteriole smooth muscle activation concomitant with changes in blood flow in a neighboring microvessel**. We made use of α-actin-BAC-GCaMP2 mice that expressed the genetically encoded Ca^2+^ indicator GCaMP2 in smooth muscle (Ji et al., [@B37]). Two-photon laser scanning microscopy was used to measure both calcium concentration and blood flow. The change in vessel diameter in the bottom line-scan data is a vasomotor event. In these transgenic animals the observable changes in \[Ca^2+^\] are limited to large contractile events; thus the present data must be considered as preliminary. Algorithms from Helmchen and Kleinfeld ([@B35]).](fnene-03-00001-g005){#F5}

![***In vivo* focal photoexcitation of channelrhodopsin-labeled astrocytes leads an increase in capillary blood flow**. We used GFAP-Cre+/− mice with an injection of adeno-associated virus serotype 2/5 with a FLEX-ChR2-tdtomato construct (Zhuo et al., [@B80]). Histological analysis shows that these animals have weak, non-specific expression of Cre recombinase in cortical neurons during adulthood, when the viral injection was made; thus the present data must be considered as preliminary. **(A)** Schematic of measurement region. **(B)** Planar image from layer 2/3, obtained with TPLSM, that includes a scanned capillary. **(C)** Change in capillary red blood cell speed upon activation of ChR2; the black line is a running average to remove heart rate contributions.](fnene-03-00001-g006){#F6}

Example Proposed Experiment
===========================

Somatosensory input leads to neuronal activation in ipsilateral parietal cortex as well as contralateral cortex, albeit with a reduced amplitude (Figures [7](#F7){ref-type="fig"}A,B). Unexpectedly, contralateral sensory input leads to net dilation of vessels, while ipsilateral input has the paradoxical effect of net constriction (Devor et al., [@B17]; Figure [7](#F7){ref-type="fig"}). One possible explanation is that contralateral input leads to rapid release of VIP while ipsilateral input preferentially excites SOM+ interneurons more slowly. One can make use of microdialysis, or for greater spatial localization an extension of CNiFER technology to form VPAC1-CNiFERs to detect vasoactive intestinal peptide and SST1-CNiFERs to detect somatostatin. We predict that the ratio of VPAC1-CNiFER to SST1-CNiFER signals will be greater for contralateral versus ipsilateral stimulation (Figure [8](#F8){ref-type="fig"}).

![**Ipsilateral versus contralateral electrophysiological and neurovascular responses to sensory input**. **(A)** Schematic of neuronal pathways. The contralateral cortex receives input via brainstem (not shown) and thalamic relays. This input is further relayed to ipsilateral cortex via collosal projections. **(B)** Measured multiunit responses to electrical stimulation of the fore-limb; 500 stimulation trials were averaged. **(C)**. Net vasodilation in surface cortical arterioles in response to somatotopic stimulation on the contralateral side (upper traces in each pair) but vasoconstriction in response to ipsilateral stimulation (lower traces). The stimulus-induced ECoG (red) identifies the locus of the electrical response. Adapted from Devor et al. ([@B17]).](fnene-03-00001-g007){#F7}

![**Proposal for observing opposing vascular changes via competition of vasoactive neuropeptides**. This proposal builds on the results in Figure [6](#F6){ref-type="fig"}, where the same sensory input leads to vasodilation at the epicenter of cortical activation in the contralateral hemisphere by vasoconstriction in the ipsilateral hemisphere. We predict that co-release of the dilator VIP dominates In the contralateral hemisphere while the constrictor SOM dominates in the ipsilateral hemisphere.](fnene-03-00001-g008){#F8}

Paradigm-Shift to Considering Neurovascular Coupling in Terms of Signaling Molecules
====================================================================================

The conventional view is that neuronal spiking leads to an increase in local metabolism, and that metabolism leads to increased oxygen extraction from the blood as well as an increase in blood speed (Fox and Raichle, [@B25]; Leybaert, [@B43]). Thus neuronal activity is mirrored by changes in blood oxygenation. This paradigm is the accepted view for the interpretation of BOLD fMRI (Logothetis et al., [@B45]). But this causal relation breaks down, as shown by a multiplicity of recent experiments (Metea and Newman, [@B51]; Devor et al., [@B17]; Gordon et al., [@B30]; Sirotin and Das, [@B62]; Girouard et al., [@B28]; Lindauer et al., [@B44]; Figure [7](#F7){ref-type="fig"}C). We envision a model of neurovascular control that maps the activity of different neuronal subtypes to changes in vascular tone (Eqs 1 and 2). In our hypothesized paradigm, neuronal activity forms the inputs, the dynamics of the underlying signaling molecules form the internal state variables, and the vascular tone is the output state variable. This is not unlike the case of neuronal dynamics, where the input is derived from synaptic activity, the opening probabilities of channels form the internal state variables, and voltage is the output.
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